Study of the Metabolism of Two Magnesium Supplements in Healthy Volunteers

Pharmacokinetic Study of Mablet as Oral Supplement and Magnesium Sulfate as Infusion

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01113138

Enrollment

Registered

2010-04-29

Start date

2012-12-31

Completion date

2014-01-31

Last updated

2014-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma, Chronic Obstructive Pulmonary Disease

Keywords

Clearance, Half-life, Absorption fraction, Pharmacokinetics

Brief summary

The present study is part of a project titled 'Magnesium in asthma and chronic obstructive pulmonary disease'. The hypothesis of the main project is that daily magnesium supplement will benefit patients with asthma and chronic obstructive pulmonary disease. The aim of this part of the project is to study the pharmacokinetics of the following two magnesium supplements: * Mablet (dietary supplement) * Magnesium Sulfate (solution for infusion)

Interventions

DIETARY_SUPPLEMENTMablet (Magnesium-supplement)

Mablet: Magnesium hydroxide/ -oxide (360 mg/tablet) 3 tablets as a single dose Produced by: Gunnar Kjems APS

DRUGMagnesium Sulfate

Solution for a single bolus-infusion, containing 2 grams of magnesium sulfate.

Study design

Allocation

NON_RANDOMIZED

Intervention model

CROSSOVER

Masking

NONE

Eligibility

Sex/Gender

MALE

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Healthy volunteers.

Exclusion criteria

* Smokers, * Using pharmaceuticals/supplements, * Vegans/vegetarians, * Major changes in eating habits within one week prior to study start.

Design outcomes

Primary

Measure	Time frame	Description
Pharmacokinetic parameters	Two years	Clearance, half-life & absorption fraction

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026